ATE331806T1 - Gegen humanen vegf-rezeptor flt-1 gerichteter, monoklonaler antikörper. - Google Patents

Gegen humanen vegf-rezeptor flt-1 gerichteter, monoklonaler antikörper.

Info

Publication number
ATE331806T1
ATE331806T1 AT97913427T AT97913427T ATE331806T1 AT E331806 T1 ATE331806 T1 AT E331806T1 AT 97913427 T AT97913427 T AT 97913427T AT 97913427 T AT97913427 T AT 97913427T AT E331806 T1 ATE331806 T1 AT E331806T1
Authority
AT
Austria
Prior art keywords
human vegf
vegf receptor
monoclonal antibody
receptor flt
directed against
Prior art date
Application number
AT97913427T
Other languages
English (en)
Inventor
Kenya Shitara
Mikito Ito
Nobuo Hanai
Masabumi Shibuya
Original Assignee
Kyowa Hakko Kogyo Kk
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kyowa Hakko Kogyo Kk filed Critical Kyowa Hakko Kogyo Kk
Application granted granted Critical
Publication of ATE331806T1 publication Critical patent/ATE331806T1/de

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57557—Immunoassay; Biospecific binding assay; Materials therefor for cancer of other specific parts of the body, e.g. brain
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AT97913427T 1996-11-21 1997-11-21 Gegen humanen vegf-rezeptor flt-1 gerichteter, monoklonaler antikörper. ATE331806T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP31110996 1996-11-21

Publications (1)

Publication Number Publication Date
ATE331806T1 true ATE331806T1 (de) 2006-07-15

Family

ID=18013261

Family Applications (1)

Application Number Title Priority Date Filing Date
AT97913427T ATE331806T1 (de) 1996-11-21 1997-11-21 Gegen humanen vegf-rezeptor flt-1 gerichteter, monoklonaler antikörper.

Country Status (8)

Country Link
US (1) US6617160B1 (de)
EP (1) EP0882799B1 (de)
JP (1) JP3746790B2 (de)
AT (1) ATE331806T1 (de)
AU (1) AU731927B2 (de)
DE (1) DE69736222T2 (de)
ES (1) ES2267136T3 (de)
WO (1) WO1998022616A1 (de)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6448077B1 (en) * 1994-02-10 2002-09-10 Imclone Systems, Inc. Chimeric and humanized monoclonal antibodies specific to VEGF receptors
US6811779B2 (en) 1994-02-10 2004-11-02 Imclone Systems Incorporated Methods for reducing tumor growth with VEGF receptor antibody combined with radiation and chemotherapy
US20030108545A1 (en) * 1994-02-10 2003-06-12 Patricia Rockwell Combination methods of inhibiting tumor growth with a vascular endothelial growth factor receptor antagonist
US6986890B1 (en) 1996-11-21 2006-01-17 Kyowa Hakko Kogyo Co., Ltd. Anti-human VEGF receptor Flt-1 monoclonal antibody
ATE331806T1 (de) 1996-11-21 2006-07-15 Kyowa Hakko Kogyo Kk Gegen humanen vegf-rezeptor flt-1 gerichteter, monoklonaler antikörper.
EP1037925A2 (de) * 1997-12-09 2000-09-27 Children's Medical Center Corporation Antagonisten für die neuropilin rezeptorfunktion und deren verwendung
WO1999037751A1 (en) * 1998-01-23 1999-07-29 Imclone Systems Incorporated Purified populations of stem cells
CA2328893A1 (en) * 1998-05-20 1999-11-25 Kyowa Hakko Kogyo Co., Ltd. Vegf activity inhibitors
ES2325642T3 (es) * 1998-05-20 2009-09-10 Kyowa Hakko Kirin Co Ltd Anticuerpos recombinantes genicos.
JP3679406B2 (ja) * 1998-05-20 2005-08-03 協和醗酵工業株式会社 遺伝子組換え抗体
WO2000052470A1 (fr) * 1999-03-04 2000-09-08 Kyowa Hakko Kogyo Co., Ltd. Moyen de diagnostic et de traitement de la leucemie
DE60040466D1 (de) * 1999-06-17 2008-11-20 Kyowa Hakko Kogyo Kk Diagnostikum und heilmittel für krankheiten unter teilnahme von makrozyten/makrophagen
JP2003528824A (ja) * 2000-02-04 2003-09-30 スプラテック ファーマ インコーポレイティド 血管内皮成長因子受容体のためのリガンド
JPWO2002031497A1 (ja) * 2000-10-11 2004-02-19 株式会社オリエントキャンサーセラピー 血管新生能の検査手段
AU2002234080A1 (en) * 2000-10-20 2002-04-29 Baylor College Of Medecine Methods for detecting retinopathy of prematurity
WO2003000183A2 (en) * 2001-06-20 2003-01-03 Imclone Systems Incorporated Method of treating atherosclerosis and other inflammatory diseases
ES2299590T3 (es) * 2001-08-10 2008-06-01 Imclone Systems, Inc. Uso medico de celulas madre que expresan vegfr-1.ng vegfr-1.
ATE475431T1 (de) * 2002-03-04 2010-08-15 Imclone Llc Kdr-spezifische humane antikörper und deren anwendung
WO2005016966A2 (en) * 2003-05-16 2005-02-24 Receptor Biologix, Inc. Intron fusion proteins, and methods of identifying and using same
CN1972712A (zh) 2003-06-09 2007-05-30 塞缪尔·瓦克萨尔 用胞外拮抗物和胞内拮抗物抑制受体酪氨酸激酶的方法
GB0323609D0 (en) * 2003-10-09 2003-11-12 Univ Belfast A peptide,and use of the peptide to assay for sflt-1 protein
CA2565974A1 (en) * 2004-05-14 2005-12-01 Receptor Biologix, Inc. Cell surface receptor isoforms and methods of identifying and using the same
US7597884B2 (en) 2004-08-09 2009-10-06 Alios Biopharma, Inc. Hyperglycosylated polypeptide variants and methods of use
US7598043B2 (en) 2004-11-19 2009-10-06 Cornell Research Foundation, Inc. Use of vascular endothelial growth factor receptor 1+ cells in treating and monitoring cancer and in screening for chemotherapeutics
JP5202956B2 (ja) * 2004-11-19 2013-06-05 コーネル リサーチ ファンデーション インコーポレーティッド 癌の治療およびモニタリングならびに化学療法薬に関するスクリーニングにおける血管内皮増殖因子受容体１＋細胞の使用法
US20090087424A1 (en) * 2004-11-26 2009-04-02 Noriko Miyamoto Modulating Retinal Pigmented Epithelium Permeaion By Inhibiting Or Activating VEGFR-1
US20090170769A1 (en) * 2005-05-13 2009-07-02 Pei Jin Cell surface receptor isoforms and methods of identifying and using the same
KR100883430B1 (ko) 2007-06-13 2009-02-12 한국생명공학연구원 혈관내피성장인자 수용체를 중화하는 인간 단클론항체 및그 용도
CN104812773B (zh) * 2012-07-20 2018-04-06 庆熙大学校产学协力团 表位标记用抗体、杂交瘤细胞株以及其用途
CN111808191A (zh) * 2020-05-11 2020-10-23 廊坊天光生物技术有限公司 一种用于检测血清中vegf含量的抗体对及其用途
CN119546307A (zh) 2022-06-30 2025-02-28 大脑和脊髓研究所 用于促进髓鞘化和神经保护的血管内皮生长因子受体-1（vegfr-1）抑制剂

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2078539C (en) 1991-09-18 2005-08-02 Kenya Shitara Process for producing humanized chimera antibody
AU669379B2 (en) 1992-09-07 1996-06-06 Kyowa Hakko Kirin Co., Ltd. Humanized antibodies
US5840301A (en) * 1994-02-10 1998-11-24 Imclone Systems Incorporated Methods of use of chimerized, humanized, and single chain antibodies specific to VEGF receptors
US5942385A (en) * 1996-03-21 1999-08-24 Sugen, Inc. Method for molecular diagnosis of tumor angiogenesis and metastasis
US6100071A (en) * 1996-05-07 2000-08-08 Genentech, Inc. Receptors as novel inhibitors of vascular endothelial growth factor activity and processes for their production
ATE331806T1 (de) 1996-11-21 2006-07-15 Kyowa Hakko Kogyo Kk Gegen humanen vegf-rezeptor flt-1 gerichteter, monoklonaler antikörper.

Also Published As

Publication number Publication date
ES2267136T3 (es) 2007-03-01
AU731927B2 (en) 2001-04-05
WO1998022616A1 (fr) 1998-05-28
US6617160B1 (en) 2003-09-09
EP0882799A4 (de) 2002-05-29
EP0882799A1 (de) 1998-12-09
AU5066698A (en) 1998-06-10
EP0882799B1 (de) 2006-06-28
JP3746790B2 (ja) 2006-02-15
DE69736222D1 (de) 2006-08-10
DE69736222T2 (de) 2007-05-24

Similar Documents

Publication Publication Date Title
ATE331806T1 (de) Gegen humanen vegf-rezeptor flt-1 gerichteter, monoklonaler antikörper.
DE69941598D1 (de) Anti-ccr2 antikörper sowie deren verwendung
EP1565489A4 (de) Neues raag10-zelloberflächenziel und dieses ziel erkennende antikörperfamilie
DE60226499D1 (de) Verwendung von antikörpern gegen das muc18-antigen
DK1616575T3 (da) Fremgangsmåde til behandling af inflammation
DE59209650D1 (de) Monoklonale antikörper gegen c-kit
DE69929235D1 (de) Spiro-indole als y5-rezeptor antagonisten
ATE490275T1 (de) Antikörper gegen interleukin-22 und verwendungen dafür
FR05C0020I2 (fr) Anticorps anti-VEGF
DZ1700A1 (fr) Morpholine et thiomorpholine comme antagonistes des récepteurs de tachydinine.
EP0743856A4 (de) Antigen-besierende heteropolymere und methoden zur behandlung von autoimmunkrankheiten mittels diesen
DE69635406D1 (de) Chemokinrezeptor 88c sowie dessen antikörper
DK69890A (da) Monoklonale antistoffer, der er reaktive med cachetin
ATE318147T1 (de) Spezifische monoklonale antikörperfür die extrazelluläre domäne von protasta-spezifischem membranantigen
EE200700052A (et) Antikeha he v?i mitme apo-lipoproteiin B fragmendi vastu
DE69533675D1 (de) Monoklonaler antikörper gegen rhesus d (d7c2)
ATE177152T1 (de) Bispezifische heteroantikörper mit zweifachen effektorfunktionen
NO992916L (no) Fosfodiesterase 8A
DE69504959D1 (de) Humanisierte monoklonale antikörper gegen humanes interleukin - 4
DE69940733D1 (de) Gen rekombinante antikörper
DK1283217T3 (da) Antistoffer mod IL-8-receptoren og deres terapeutiske anvendelser
FI853389L (fi) Tumoerlaekemedel och foerfarande foer dess framstaellning.
CA2243302A1 (en) Anti-human vegf receptor f1t-1 monoclonal antibody
WO2002064023A3 (en) Fra-1 expression in brain cancer
ATE139704T1 (de) Verwendung und verabreichung von enzymen

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties